Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells, ch14.18 and Lenalidomide

Trial Profile

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells, ch14.18 and Lenalidomide

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs Dinutuximab (Primary) ; Lenalidomide
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Acronyms NANT
  • Most Recent Events

    • 17 Jan 2018 Planned End Date changed from 1 Jan 2021 to 1 Apr 2021.
    • 17 Jan 2018 Planned primary completion date changed from 1 Jul 2020 to 1 Oct 2020.
    • 17 Jan 2018 Planned initiation date changed from 1 Feb 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top